Pharmaceutical technology and product companies have emerged as hot targets for China’s overseas acquisitions this summer, as the country is keen to rapidly upgrade its pharmaceutical industry. Eight M&As were observed in the past two months, bringing back advanced technologies and products to help domestic development, as well as facilitate global expansion.
The most recent example is the asset acquisition of California-based SynGen completed by Chinese Boyalife Group through its wholly-own subsidiary...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

